Year Founded
2017
Ownership
Private
Employees
~10
Therapeutic Areas
Dermatology
Stage
Phase 2
Modalities
Small molecule

CAGE Bio General Information

Positive Phase 2 results for 1% tofacitinib ionic liquid formulation in atopic dermatitis

Contact Information

Website
Primary Industry
Biotech
Corporate Office
San Carlos, California
United States

Drug Pipeline

tofacitinib
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to CAGE Bio's pipeline data

Book a demo

Key Partnerships

Johnson & Johnson Innovation (JLABS resident), TAGCyx, PeptiStar

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CAGE Bio Funding

Deal TypeDateAmountStatusStage
Later Stage VCFeb 16, 2021$7.2MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CAGE Bio's complete valuation and funding history, request access »